Pre-clinical Data Shows Potential to Force Cancer Cells into Less Malignant States
LIXTE Biotechnology Holdings, Inc. has made a groundbreaking advancement in cancer treatment with its lead clinical compound, LB-100, as revealed in a recent publication in Cancer Discovery. The pre-clinical data highlights LB-100’s ability to induce cancer cells to relinquish their cancer-causing properties, presenting a promising new avenue in cancer therapy.
LB-100 demonstrated a paradoxical effect by hyper-activating signals responsible for the uncontrolled proliferation of cancer cells, unlike conventional cancer treatments. When combined with a WEE1 kinase inhibitor, this approach proved highly effective in eliminating colon cancer cells in animal models and cell cultures, offering a potential solution to therapy resistance—a major challenge in cancer treatment.
Moreover, LB-100-induced resistance was associated with cancer cells adopting less malignant behaviors, inhibiting tumor formation in experimental models. This unique mechanism, coined “tumor suppressive drug resistance,” presents a novel concept in cancer therapy.
Led by Professor René Bernards, a renowned figure in molecular carcinogenesis, the research team’s findings open new horizons for cancer treatment. LIXTE’s CEO, Bas van der Baan, expressed optimism about clinically testing LB-100’s unique approach, marking a significant departure from conventional cancer therapies.
Read original press release:here
You might like this article:Moderna Unveils Promising New Vaccine Candidates Beyond COVID
